Adam Waldman
Corporate Officer/Principal presso TG THERAPEUTICS, INC.
Profilo
Adam Waldman is currently the Chief Commercial Officer at TG Therapeutics, Inc. He previously worked at Celgene Corp.
as the Head of Haematology & Oncology Marketing.
Waldman received an undergraduate degree from Rutgers State University of New Jersey and an MBA from the University of Rochester Simon Business School.
Posizioni attive di Adam Waldman
| Società | Posizione | Inizio |
|---|---|---|
| TG THERAPEUTICS, INC. | Corporate Officer/Principal | 04/06/2018 |
Precedenti posizioni note di Adam Waldman
| Società | Posizione | Fine |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
Formazione di Adam Waldman
| Rutgers State University of New Jersey | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| TG THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Borsa valori
- Insiders
- Adam Waldman
